Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPITECH: Early COMT Inhibition vs Levodopa Escalation in Parkinson's Disease
NCT07917546Completed
- Sponsor
- Neuromed Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised, single-blind trial of opicapone in Parkinson's disease (PD) (2 arms), sponsored by Neuromed Pharmaceuticals. Primary endpoint: Change in Wearable-Derived Daily OFF Time at 4 weeks. Started Jan 2024; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07917546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917546.